Recipient: Helmholtz-Zentrum für Infektionsforschung GmbH (Helmholtz Centre for Infection Research)
Funding: GO-Bio initial conceptual phase 4 (01/10/2023 to 30/09/2024, EUR 98,489.39)

Project description:

Suitable vaccine platforms are the basis for the successful development of vaccines. One possibility is the use of viral vectors as a vaccine platform. Vectors from the herpes virus family are known to produce strong and long-lasting immune responses. So far, however, there are no approved vaccines based on this technology. On the basis of a unique approach that circumvents the previously known problems of this technology, the VIVA-VEK project aims to identify and evaluate the optimal uses for a novel vaccine vector. The novel vaccine platform based on this is thus expected to make a long-term contribution to the development of innovative vaccines. In the upcoming exploratory phase a pathogen-specific vaccine candidate for further development will be specified and the goals for a feasibility phase and ideal partners for this will be identified. Ultimately, in cooperation with experts from the Paul-Ehrlich Institute, the prerequisites for clinical trials will be developed to be able to address them systematically during the feasibility phase.